CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Soft Tissue Sarcoma
Special Reports in Personalized Cancer Care
Online Continuing Education Activities
SELECT A TOPIC
<< View More Conferences
2016 SITC Meeting
Oncology Conference Multimedia
View more videos >>
Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLC
Susan Lutgendorf on Impact of Minimal Support on Patients With Ovarian Cancer
Lisa Butterfield on SITC Immune Biomarkers Task Force
Oncology Conference Articles
Emerging Immune Checkpoint Holds Promise for Blockade Strategies
A novel immune checkpoint called PVRIG is currently in development.
Dual Biomarker Signature Holds Predictive Promise for Response to Anti-PD-L1 Therapy in NSCLC
Recent research suggests that the presence of PD-L1–positive and CD8+ cells may be useful for predicting responses in patients with non-small cell lung cancer who have been treated with durvalumab.
Nivolumab/Ipilimumab Combo Highly Effective for Pretreated Metastatic Urothelial Carcinoma
The combination of nivolumab and ipilimumab led to a high response rate and improved overall survival versus historical controls for patients with pretreated metastatic urothelial carcinoma.
Pembrolizumab OS Benefit Sets New Benchmark in Second-Line Bladder Cancer
Pembrolizumab monotherapy reduced the risk of death by 27% compared with chemotherapy for patients with advanced urothelial carcinoma whose disease progressed after prior treatment.
Lirilumab/Nivolumab Combo Highly Effective in Head and Neck Cancer
The combination of lirilumab and nivolumab resulted in an objective response rate of 24.1% in patients with squamous cell carcinoma of the head and neck.
NDA Withdrawn in Melanoma, Promising Phase III Results in Breast Cancer and Ovarian Cancer, and More
FDA Approves Niraparib for Ovarian Cancer
Expert Discusses QoL Benefits of Active Surveillance for Low-Risk Prostate Cancer
FDA Panel Supports Subcutaneous Rituximab for Blood Cancers
Overcoming Resistance to HER2-Targeted Therapy in Breast Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2017
Intellisphere, LLC. All Rights Reserved.